A 2-year multicentre, open-label, randomized, controlled study of growth hormone (Genotropin®) treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN) Study

Summary Objective In Europe, growth hormone (GH) treatment for children born small for gestational age (SGA) can only be initiated after 4 years of age. However, younger age at treatment initiation is a predictor of favourable response. To assess the effect of GH treatment on early growth and cognit...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical endocrinology (Oxford) 2016-03, Vol.84 (3), p.353-360
Hauptverfasser:	De Schepper, Jean, Vanderfaeillie, Johan, Mullis, Primus-E., Rooman, Raoul, Robertson, Anna, Dilleen, Maria, Gomez, Roy, Wollmann, Hartmut A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenoids - pathology Body Height - drug effects Child Development - drug effects Child, Preschool Female Human Growth Hormone - administration & dosage Human Growth Hormone - adverse effects Human Growth Hormone - therapeutic use Humans Hypertrophy - chemically induced Infant Infant, Newborn Infant, Small for Gestational Age Injections, Subcutaneous Male Psychomotor Performance - drug effects Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Objective In Europe, growth hormone (GH) treatment for children born small for gestational age (SGA) can only be initiated after 4 years of age. However, younger age at treatment initiation is a predictor of favourable response. To assess the effect of GH treatment on early growth and cognitive functioning in very young (
ISSN:	0300-0664 1365-2265
DOI:	10.1111/cen.12968